PharmaTelevision - Bailard Investments: New Pathways for Investment Opportunities

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Bailard Investments: New Pathways for Investment Opportunities

Visitors: You are watching a 30 seconds preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks with Selena Chaisson, Director of Healthcare Investments at Bailard.

Filmed at AusBiotech 2009, they discuss:

• 2009 performance in the public markets
• Bailard's criteria for investment
• how investing at early stages is the way forward
• IPO potential, with more to come in Biotech
• scouting Australia for new investment opportunities

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Bailard:The funds and activities.

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here in Melbourne, Australia on this show I have Selene Chaisson who is the director of Investments at Bailard Investments, welcome to the show.

Selene Chaisson:

Thank you, Thank you for inviting me.

Fintan Walton:

Selene Chaisson you are a been in the investing in healthcare for many many years. You've got for with some of the larger funds in the US investing in healthcare. You are currently at Bailard and you are investing in publicly quoted companies and you've got a number of funds could you tell us a little bit about Bailard and the activities you have right now?

Selene Chaisson:

Yeah Bailard is a primarily high networth individuals and we have about 1.6 billion under management currently and about half of that is in real estate investments and the other half is in equities and there are three funds that can invest in life sciences companies. One is an emerging growth fund, the other is a small cap value fund and then that we have our emerging life sciences fund.

Fintan Walton:

So the size of these funds give us some idea.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Selene Chaisson
Director of Healthcare Investments
Bailard

Bailard

We at Bailard offer innovative, well-designed investment products to insitutional and individual investors. Our mission is to create investment opportunities for clients through our:

Think-tank culture
Our disciplined, collaborative approach to investment management stimulates innovative thinking and enables us to find new ways to make money for our clients.

Different view of risk
Our approach to risk is disciplined and intelligent and seeks to offer clients the opportunity for solid returns and a smoother ride.

Stability and agility
We've lived through market cycles, seen bubbles come and go. Our collective knowledge and long-term perspective enable us to nimbly adapt to market changes and find value for our clients.

Refreshing approach to client service
It's personal, dialogical, and focused on building long-term relationships. It's all about identifying issues, solving problems, and making money for our clients. And it works: many of our clients have been with us for more than two decades.